Trazodone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Trazodone: From Depression to Obsessive-Compulsive Disorder
One-Sentence Summary
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) established as an antidepressant for the treatment of depression. The TxGNN model predicts it may be effective for Obsessive-Compulsive Disorder (OCD), with no currently registered clinical trials but 20 published studies, including one double-blind, placebo-controlled trial, supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (based on established antidepressant classification; no formal licensing/indication text available in this dataset) |
| Predicted New Indication | Obsessive-Compulsive Disorder (OCD) |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L2 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this dataset. Based on known pharmacology, trazodone is a serotonin antagonist and reuptake inhibitor (SARI), combining 5-HT2A/2C receptor antagonism with weak serotonin reuptake inhibition. Its efficacy as an antidepressant has been established, and mechanistically it may be applicable to OCD.
OCD is understood to involve dysregulation of the serotonin (5-HT) system, and the disorder is preferentially responsive to potent serotonin reuptake inhibitors such as clomipramine, fluoxetine, fluvoxamine and paroxetine. Trazodone’s serotonergic modulation therefore has a theoretical, partially overlapping link with these established OCD treatments. However, trazodone’s dominant pharmacological action is 5-HT2A receptor antagonism rather than potent serotonin transporter (SERT) inhibition, which is the mechanism most strongly associated with efficacy in OCD — meaning the mechanistic fit is plausible but not fully aligned with the current standard of care.
This partial mechanistic overlap is reflected in the evidence base: a small double-blind, placebo-controlled trial and several open-label/cohort studies (including one using PET imaging to correlate symptom response with caudate glucose metabolism) suggest a possible, modest benefit, particularly in patients who have failed clomipramine. The evidence is nonetheless dated (predominantly 1984–1996) and has not been corroborated by modern, adequately powered randomised trials.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1629380 | 1992 | RCT (double-blind, placebo-controlled) | Journal of Clinical Psychopharmacology | Controlled trial investigating trazodone’s anti-obsessional efficacy in OCD, given its serotonin reuptake-inhibiting properties. |
| 8993077 | 1996 | Review | Psychopharmacology Bulletin | Reviews mono- and polypharmacotherapy of OCD; notes that only potent serotonin reuptake inhibitors were FDA-approved for OCD at the time. |
| 27744763 | 2017 | Review | Postgraduate Medicine | Comprehensive review of trazodone’s mechanism, formulation and use in psychiatric/medical conditions, including non-FDA-approved use in OCD. |
| 2119885 | 1990 | Cohort/Open-label | Clinical Neuropharmacology | Trazodone administered to 9 clomipramine-resistant OCD patients; mild but significant improvement overall, with 3 clear responders. |
| 3501130 | 1987 | Cohort (PET/glucose metabolism study) | Psychopathology | Trazodone response in OCD correlated with changes in caudate nucleus glucose metabolism on PET imaging. |
| 8434675 | 1993 | Case series | American Journal of Psychiatry | Reports trazodone treatment outcomes in OCD and comorbid trichotillomania. |
| 26088119 | 2015 | Review | Current Pharmaceutical Design | Discusses off-label trazodone use, including OCD, alongside insomnia, GAD, panic disorder and PTSD, weighing evidence, benefits and risks. |
| 4009160 | 1985 | Case report | Journal of Nervous and Mental Disease | Two patients with OCD and comorbid depression, refractory to other antidepressants, showed rapid improvement on trazodone. |
| 8331098 | 1993 | Review | Journal of Clinical Psychiatry | Reviews biological/augmentation strategies for treatment-resistant OCD, mainly combining SRIs with adjunct agents. |
| 8134850 | 1994 | Review | Southern Medical Journal | Reviews pharmacologic management of OCD in the context of serotonin/dopamine dysregulation hypotheses. |
UK Market Information
No MHRA marketing authorisation is recorded for trazodone in this dataset (market status: Not Marketed, 0 licences). Regulatory and licensing details should be verified directly against the current MHRA and BNF records before further evaluation.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: A single small double-blind, placebo-controlled trial plus several dated open-label, cohort and case-report studies suggest a plausible but modest benefit of trazodone in OCD, largely in clomipramine-resistant patients. However, there are no registered clinical trials, no confirmed UK marketing authorisation, and critical safety data (SmPC warnings, contraindications, drug interactions) are currently unavailable — the latter being a blocking gap for any initial safety assessment.
To proceed, the following is needed:
- MHRA/UK SmPC warnings and contraindications (currently a blocking data gap)
- Detailed mechanism of action (MOA) data from DrugBank or equivalent source
- Confirmation of current UK licensing/marketing status and the formally approved original indication text
- Updated systematic review or a modern, adequately powered RCT evaluating trazodone specifically in OCD
- Completed drug-drug interaction (DDI) profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.